HRP20191999T1 - Monoklonska protutijela anti-faktora xi i postupci njihove uporabe - Google Patents
Monoklonska protutijela anti-faktora xi i postupci njihove uporabe Download PDFInfo
- Publication number
- HRP20191999T1 HRP20191999T1 HRP20191999TT HRP20191999T HRP20191999T1 HR P20191999 T1 HRP20191999 T1 HR P20191999T1 HR P20191999T T HRP20191999T T HR P20191999TT HR P20191999 T HRP20191999 T HR P20191999T HR P20191999 T1 HRP20191999 T1 HR P20191999T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- antigen
- polynucleotide
- binding fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 239000012634 fragment Substances 0.000 claims 14
- 102000040430 polynucleotide Human genes 0.000 claims 14
- 108091033319 polynucleotide Proteins 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010053567 Coagulopathies Diseases 0.000 claims 3
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 101001062768 Homo sapiens Coagulation factor XI Proteins 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 108010074864 Factor XI Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 230000006957 competitive inhibition Effects 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Izolirano monoklonsko protutijelo ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski faktor koagulacije XI (FXI) opisan u SEQ ID NO: 1, pri čemu protutijelo ili fragment inhibira trombozu bez nanošenja štete sustavu hemostaze, te time da navedeno protutijelo:
(i) obuhvaća varijabilnu domenu (VH) teškog lanca, koja sadrži tri regije određivanja komplementarnosti (CDR - engl. complementarity determining region), gdje tri CDR-regije sadrže tri CDR-sekvence od SEQ ID NO: 3 ili SEQ ID NO: 7, kao što se određuje uporabom Kabat sustava numeriranja; i
varijabilnu domenu (VL) lakog lanca, koja sadrži tri CDR-regije, gdje tri CDR-regije sadrže tri CDR-sekvence od SEQ ID NO: 5 ili SEQ ID NO: 9, kao što se određuje uporabom Kabat sustava numeriranja; ili
(ii) kompetitivno inhibira vezanje protutijela koje obuhvaća varijabilnu domenu (VH) teškog lanca od SEQ ID NO: 3 i varijabilnu domenu (VL) lakog lanca od SEQ ID NO: 5 na ljudski FXI s barem 90%, pri čemu se kompetitivno inhibiranje određuje pomoću kompetitivnog testiranja imunosorpcije povezane s enzimom (ELISA- engl. enzyme-linked immunosorbent assay).
2. Izolirano monoklonsko protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1, naznačeno time, da
barem jedna od tri CDR-regije VH domene obuhvaća aminokiselinsku sekvencu od SEQ ID NO: 10, SEQ ID NO: 11 ili SEQ ID NO: 12, gdje prema potrebi tri CDR-regije od VH domene sadrže aminokiselinske sekvence od SEQ ID NO: 10, SEQ ID NO: 11 i SEQ ID NO: 12, i/ili
barem jedna od tri CDR-regije VL domene obuhvaća aminokiselinsku sekvencu od SEQ ID NO: 13, SEQ ID NO: 14 ili SEQ ID NO: 15, gdje prema potrebi tri CDR-regije od VL domene sadrže aminokiselinske sekvence od SEQ ID NO: 13, SEQ ID NO: 14 i SEQ ID NO: 15.
3. Izolirano monoklonsko protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time, da
je aminokiselinska sekvenca od VH domene najmanje 90% identična sa SEQ ID NO: 3 ili SEQ ID NO: 7, dok prema potrebi aminokiselinska sekvenca od VH domene sadrži SEQ ID NO: 3 i SEQ ID NO: 7; i/ili
je aminokiselinska sekvenca od VL domene najmanje 90% identična sa SEQ ID NO: 5 ili SEQ ID NO: 9, dok prema potrebi aminokiselinska sekvenca od VL domene sadrži SEQ ID NO: 5 i SEQ ID NO: 9.
4. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 3, naznačeno time, da se upotrebljava u postupku liječenja tromboze povezane s koagulopatijom kod pojedinca kojemu je to potrebno, pri čemu postupak obuhvaća davanje pojedincu učinkovite doze protutijela ili fragmenta, gdje je prema potrebi pojedinac sisavac, a opcijski je to primat koji nije čovjek.
5. Protutijelo ili njegov fragment koji veže antigen, za uporabu prema patentnom zahtjevu 4, naznačeno time, da pojedinac je čovjek.
6. Protutijelo ili njegov fragment koji veže antigen, za uporabu prema patentnom zahtjevu 4 ili zahtjevu 5, naznačeno time, da se u navedenom postupku spomenuto protutijelo ili fragment primjenjuje kod navedenog pojedinca u jedinstvenoj dozi od 0,01 mg/kg do 10 mg/kg, prema potrebi u jedinstvenoj dozi od 2 mg/kg.
7. Protutijelo ili njegov fragment koji veže antigen, za uporabu prema bilo kojem od patentnih zahtjeva 4 do 6, naznačeno time, da koagulopatija obuhvaća diseminiranu intravaskularnu koagulaciju (DIK).
8. Protutijelo ili njegov fragment koji veže antigen, za uporabu prema bilo kojem od patentnih zahtjeva 4 do 6, naznačeno time, da koagulopatija obuhvaća akutni respiratorni distresni sindrom (ARDS).
9. Protutijelo ili njegov fragment koji veže antigen, za uporabu prema patentnom zahtjevu 7 ili zahtjevu 8, naznačeno time, da pojedinac ima infekciju, pri čemu je opcijski ta infekcija virusna infekcija.
10. Protutijelo ili njegov fragment koji veže antigen, za uporabu prema patentnom zahtjevu 7 ili zahtjevu 8, naznačeno time, da pojedinac ima rak.
11. Izolirani polinukleotid, naznačen time, da kodira protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 3.
12. Izolirani polinukleotid prema patentnom zahtjevu 11, naznačen time, da obuhvaća polinukleotidnu sekvencu odabranu iz skupine koja se sastoji od:
a) polinukleotidne sekvence prikazane u SEQ ID NO: 2 ili 6;
b) polinukleotidne sekvence koja ima najmanje 85% identiteta sekvence od polinukleotidne sekvence prikazane u SEQ ID NO: 2 ili 6.
13. Izolirani polinukleotid prema patentnom zahtjevu 11, naznačen time, da obuhvaća polinukleotidnu sekvencu odabranu iz skupine koja se sastoji od:
a) polinukleotidne sekvence prikazane u SEQ ID NO: 4 ili 8;
b) polinukleotidne sekvence koja ima najmanje 85% identiteta sekvence od polinukleotidne sekvence prikazane u SEQ ID NO: 4 ili 8.
14. Pripravak ili stanica domaćina, naznačen/a time, da obuhvaća polinukleotid u skladu s bilo kojim od patentnih zahtjeva 11 do 13.
15. Vektor, naznačen time, da obuhvaća polinukleotid u skladu s bilo kojim od patentnih zahtjeva 11 do 13, pri čemu je navedeni polinukleotid, prema potrebi, operativno povezan s promotorom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98952307P | 2007-11-21 | 2007-11-21 | |
| EP15189714.7A EP3002298B1 (en) | 2007-11-21 | 2008-11-21 | Anti-factor xi monoclonal antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191999T1 true HRP20191999T1 (hr) | 2020-02-07 |
Family
ID=40568500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191999TT HRP20191999T1 (hr) | 2007-11-21 | 2019-11-05 | Monoklonska protutijela anti-faktora xi i postupci njihove uporabe |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US8236316B2 (hr) |
| EP (2) | EP3002298B1 (hr) |
| JP (1) | JP2011504371A (hr) |
| AU (1) | AU2008326348B2 (hr) |
| CA (1) | CA2705851C (hr) |
| CY (1) | CY1122270T1 (hr) |
| DK (2) | DK3002298T3 (hr) |
| ES (2) | ES2566963T3 (hr) |
| HK (1) | HK1223114A1 (hr) |
| HR (1) | HRP20191999T1 (hr) |
| HU (1) | HUE046564T2 (hr) |
| LT (1) | LT3002298T (hr) |
| PL (1) | PL3002298T3 (hr) |
| PT (1) | PT3002298T (hr) |
| SI (1) | SI3002298T1 (hr) |
| WO (1) | WO2009067660A2 (hr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3002298T1 (sl) * | 2007-11-21 | 2019-12-31 | Oregon Health & Science University | Monoklonska protitelesa proti faktorju XI in postopki njihove uporabe |
| US20110159006A1 (en) * | 2008-06-19 | 2011-06-30 | Erik Hack | Use of anti-factor xi antibodies for prevention of thrombus formation |
| HUE035888T2 (en) | 2008-10-15 | 2018-05-28 | Ionis Pharmaceuticals Inc | Modulation of Factor 11 Expression |
| TR201904662T4 (tr) | 2008-12-18 | 2019-05-21 | Gruber Andras | Anti-fxı antikorları ve kullanma yöntemleri. |
| RU2011146158A (ru) * | 2009-04-15 | 2013-05-27 | АйЭсАйЭс ФАРМАСЬЮТИКАЛЗ, ИНК. | Модуляция воспалительных реакций фактором хi |
| JP6025570B2 (ja) * | 2010-03-01 | 2016-11-16 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 組織因子経路インヒビター（ｔｆｐｉ）に対する最適化されたモノクローナル抗体 |
| EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| US9352016B2 (en) | 2011-03-09 | 2016-05-31 | Csl Behring Gmbh | Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| EP2847228B1 (en) | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| WO2014089493A1 (en) | 2012-12-07 | 2014-06-12 | Vanderbilt University | Antibodies against factor xii and uses thereof |
| CA2899594A1 (en) * | 2013-02-01 | 2014-08-07 | Keith A. Moskowitz | Blood collection devices containing contact pathway inhibition additives |
| ES2844189T3 (es) | 2013-03-08 | 2021-07-21 | Csl Behring Gmbh | Tratamiento y prevención de lesiones remotas por isquemia-reperfusión |
| EP3194437B1 (en) | 2014-08-07 | 2021-01-20 | Novartis AG | Angiopoietin-like 4 (angptl4) antibodies and methods of use |
| CA2957219A1 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| JOP20200312A1 (ar) * | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| WO2017015619A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
| KR20180104036A (ko) | 2016-01-22 | 2018-09-19 | 머크 샤프 앤드 돔 코포레이션 | 항-응고 인자 xi 항체 |
| KR102448456B1 (ko) * | 2016-03-23 | 2022-09-28 | 프로틱스 비브이 | 인자 xi의 활성 부위에 대한 모노클로날 항체 및 이의 용도 |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| PE20190416A1 (es) * | 2016-06-14 | 2019-03-19 | Merck Sharp & Dohme | Anticuerpos antifactor de la coagulacion xi |
| EP3293593B1 (en) * | 2016-09-12 | 2019-03-20 | Sandvik Intellectual Property AB | Method for estimating error propagation |
| EP3515947B1 (en) | 2016-09-20 | 2024-05-29 | Aronora, Inc. | Novel antibodies against factor xi and uses thereof |
| AU2017383232A1 (en) * | 2016-12-23 | 2019-06-27 | Novartis Ag | Factor XI antibodies and methods of use |
| CA3048157A1 (en) * | 2016-12-23 | 2018-06-28 | Novartis Ag | Methods of treatment with anti-factor xi/xia antibodies |
| CN108409863B (zh) * | 2017-02-10 | 2023-09-26 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
| CN111902427A (zh) | 2017-11-22 | 2020-11-06 | 诺华股份有限公司 | 抗因子XI/XIa抗体的逆转结合剂及其用途 |
| US11155638B2 (en) | 2018-05-08 | 2021-10-26 | Rhode Island Hospital | Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications |
| AU2019266261A1 (en) | 2018-05-09 | 2020-11-05 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing FXI expression |
| MX2021001613A (es) * | 2018-08-09 | 2021-04-28 | Shanghai Benemae Pharmaceutical Corp | Anticuerpos anti-factor xi. |
| KR20230035079A (ko) * | 2020-07-03 | 2023-03-10 | 수조우 알파맵 씨오., 엘티디. | 응고인자 xi(fxi) 결합 단백질 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE68921982D1 (de) | 1988-06-14 | 1995-05-04 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
| JPH09506761A (ja) | 1990-11-09 | 1997-07-08 | ステファン ディー．ギリーズ | サイトカインの免疫複合体 |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US20030235587A1 (en) * | 1998-08-07 | 2003-12-25 | Feuerstein Giora Z. | Anticoagulant agents useful in treatment of thrombosis |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6623960B1 (en) * | 1999-02-12 | 2003-09-23 | The United States Of America As Represented By The Department Of Health And Human Services | Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19 |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| EP1825864A3 (en) * | 2000-05-15 | 2007-09-12 | SmithKline Beecham Corporation | Antithrombotic agents |
| CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20080138837A1 (en) * | 2004-07-19 | 2008-06-12 | Robert Greenfield | Methods and kits for detecting and measuring ADAMTS13/FXI complexes |
| CA2584859C (en) * | 2004-10-25 | 2017-11-07 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
| US7859456B2 (en) | 2006-10-10 | 2010-12-28 | Sirf Technology Holdings, Inc. | Method of mixed data assisted and non data assisted navigation signal acquisition, tracking and reacquisition |
| EP2152750A1 (en) * | 2007-04-23 | 2010-02-17 | Schering Corporation | Anti-mdl-1 antibodies |
| SI3002298T1 (sl) * | 2007-11-21 | 2019-12-31 | Oregon Health & Science University | Monoklonska protitelesa proti faktorju XI in postopki njihove uporabe |
| US20110159006A1 (en) | 2008-06-19 | 2011-06-30 | Erik Hack | Use of anti-factor xi antibodies for prevention of thrombus formation |
| CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2575473B1 (en) | 2010-05-27 | 2016-01-20 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2687210A1 (de) | 2010-06-25 | 2014-01-22 | Bayer Intellectual Property GmbH | Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen |
| CN106977530A (zh) | 2010-07-09 | 2017-07-25 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| CN103619845B (zh) | 2011-04-21 | 2016-08-17 | 拜耳知识产权有限责任公司 | 氟烷基取代的吡唑并吡啶及其用途 |
| JP5976788B2 (ja) | 2011-05-06 | 2016-08-24 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用 |
| WO2013030138A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| EA026701B1 (ru) | 2011-09-02 | 2017-05-31 | Байер Интеллектуэль Проперти Гмбх | Замещенные аннелированные пиримидины, способ их получения, их применение и лекарственное средство для лечения и/или профилактики заболеваний |
| EP2847228B1 (en) | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
-
2008
- 2008-11-21 SI SI200832100T patent/SI3002298T1/sl unknown
- 2008-11-21 HU HUE15189714A patent/HUE046564T2/hu unknown
- 2008-11-21 LT LT15189714T patent/LT3002298T/lt unknown
- 2008-11-21 JP JP2010535088A patent/JP2011504371A/ja not_active Withdrawn
- 2008-11-21 DK DK15189714T patent/DK3002298T3/da active
- 2008-11-21 DK DK08852770.0T patent/DK2222707T3/en active
- 2008-11-21 EP EP15189714.7A patent/EP3002298B1/en not_active Revoked
- 2008-11-21 WO PCT/US2008/084336 patent/WO2009067660A2/en active Application Filing
- 2008-11-21 AU AU2008326348A patent/AU2008326348B2/en not_active Ceased
- 2008-11-21 US US12/744,037 patent/US8236316B2/en active Active
- 2008-11-21 EP EP08852770.0A patent/EP2222707B1/en not_active Not-in-force
- 2008-11-21 CA CA2705851A patent/CA2705851C/en not_active Expired - Fee Related
- 2008-11-21 ES ES08852770.0T patent/ES2566963T3/es active Active
- 2008-11-21 ES ES15189714T patent/ES2755376T3/es active Active
- 2008-11-21 PL PL15189714T patent/PL3002298T3/pl unknown
- 2008-11-21 PT PT151897147T patent/PT3002298T/pt unknown
-
2012
- 2012-04-13 US US13/446,320 patent/US8399648B2/en active Active
-
2013
- 2013-03-04 US US13/783,952 patent/US20130171144A1/en not_active Abandoned
-
2014
- 2014-04-01 US US14/242,692 patent/US9125895B2/en active Active
-
2015
- 2015-07-27 US US14/809,551 patent/US9636399B2/en active Active
-
2016
- 2016-09-29 HK HK16111374.5A patent/HK1223114A1/zh unknown
-
2017
- 2017-03-27 US US15/470,758 patent/US20170204195A1/en not_active Abandoned
-
2018
- 2018-07-30 US US16/049,141 patent/US10577428B2/en active Active
-
2019
- 2019-11-05 HR HRP20191999TT patent/HRP20191999T1/hr unknown
- 2019-11-06 CY CY20191101163T patent/CY1122270T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191999T1 (hr) | Monoklonska protutijela anti-faktora xi i postupci njihove uporabe | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| RU2020120539A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| JP2012525829A5 (hr) | ||
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| HRP20190917T1 (hr) | NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE | |
| JP2015514110A5 (hr) | ||
| HRP20110758T1 (hr) | Antagonistička protutijela na il-17 | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| RU2012153968A (ru) | Композиции и способы лечения инфекций и опухолей | |
| HRP20130922T1 (hr) | U potpunosti humana protutijela protiv humanog 4-1bb (cd137) | |
| RU2018112861A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20140316T1 (hr) | Humana antitijela protiv virusa hepatitisa c (hcv) i njihova uporaba | |
| JP2012532851A5 (hr) | ||
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| HRP20171775T1 (hr) | Molekule protutijela koje vežu trombin i njihova uporaba | |
| AU2015359262B2 (en) | Method for the treatment of idiopathic pulmonary fibrosis | |
| JP2017529324A5 (hr) | ||
| RU2016101716A (ru) | Терапевтический агент, содержащий гуманизированное антиэпирегулиновое антитело в качестве действующего ингредиента для немелкоклеточной карциномы легкого, за исключением аденокарциномы |